Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes

Solvay

Status and phase: Completed; Phase 3; Phase 2

Conditions: Dyslipidemia/Glucose Metabolism Disorder

Treatments: Drug: fenofibrate and metformin combination (drug)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00349128

C LF23-0121 03 01

Details and patient eligibility

About

The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes mellitus

Exclusion criteria

• Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose > 300 mg/dL - Triglycerides > 500 mg/dL

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind